Umoja Biopharma | $100,000,000 | (Jan 21, 2025)
Fundment | $55,157,175 | (Jan 21, 2025)
r4 | $1,000,000 | (Jan 21, 2025)
PhaseV
United States
- Boston, Massachusetts
- 25/10/2023
- Unknown
- $15,000,000
PhaseV is leveraging cutting-edge algorithms such as reinforcement learning and causal ML for adaptive trial design and closed-loop execution, in order to improve trial success rate while maximizing resource and time efficiency. Our novel methodology and advanced technology also enable the detection of hidden signals in data while analyzing clinical trial results and extracting actionable insights.
- Industry Pharmaceutical Manufacturing
- Website https://phasevtrials.com/
- LinkedIn https://www.linkedin.com/company/phasevtrials/about/
Related People
Raviv PrylukCo Founder
Israel -
Tel Aviv-Yafo, Tel Aviv District
Experienced executive & leader of technology and operations teams. A passion for solving complex multidisciplinary problems in a data-driven and results-oriented manner for making a broad and positive impact in the world. Long track record of excellence across several fields and industries - engineering, machine learning, data science, biotechnology, computational neuroscience (Ph.D.), and more.
IntusCare | $11,500,000 | (Jan 21, 2025)
Alteva Technologies | $1,760,526 | (Jan 21, 2025)
ecoplanet | $16,571,680 | (Jan 21, 2025)
StepChange.work | $4,000,000 | (Jan 21, 2025)
Sereact | $25,894,660 | (Jan 21, 2025)
Men In Blazers Media Network | $150,000,000 | (Jan 21, 2025)
Pipe17 | $15,500,000 | (Jan 17, 2025)
Coram AI | $13,800,000 | (Jan 17, 2025)
Quantifind | $22,000,000 | (Jan 17, 2025)